Incyte and Merck update on epacadostat and Keytruda collaboration

31 March 2017

Additional details have been announced of the clinical development program investigating the combination of epacadostat, Incyte Corp’s (Nasdaq: INCY) investigational oral selective IDO1 enzyme inhibitor, with Keytruda (pembrolizumab), Merck & Co’s (NYSE: MRK) anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN).

The expanded collaboration now includes seven pivotal studies:

A Phase III study in metastatic melanoma (trial underway);
two Phase III studies in first-line NSCLC, including both PD-L1 high-expressing and PD-L1 unselected populations;
two Phase III studies in bladder cancer, including one in first-line bladder cancer and one in second-line bladder cancer;
a Phase III study in first-line RCC; and
a Phase III study in first-line SCCHN.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK